The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
There were increases in rates of new testing, testosterone initiation and initiation without a recent test.
Although the HPV vaccine is recommended, too few are getting it, researchers say.
There were significantly increased odds of headache for men in the lowest versus highest serum 25(OH)D quartile.
Resveratrol, a natural compound found in red wine and grapes, increased spinal bone density in men with metabolic syndrome and could hold promise as a treatment for osteoporosis, according to a new study published in the Endocrine Societys Journal of Clinical Endocrinology Metabolism.
Older men whose testosterone levels were neither low nor high tended to live longer, according to new research accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology Metabolism.
Testosterone is a key male sex hormone involved in maintaining sex drive, sperm production and bone health. Physicians have long known that low testosterone levels can signal health problems, but the new study found men may not fare better when levels of the hormone rise too high.
A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exerts that effect. The researchers also suggest why, despite its potential lethality, the genetic variation has been favored by natural selection to become common in light-skinned people. It appears this mutation might aid the tanning of Caucasian skin in response to sunlight, protecting it from UV radiation, which can burn and cause cancer.
Guideline provides detailed direction on treatment options for prostate cancer patients
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence. The 81-page document represents an intensive collaboration among experts in the radiation oncology and urology fields, led by Richard K. Valicenti, MD, MA, professor and chair of the department of radiation oncology at the University of California Davis Comprehensive Cancer Center in Sacramento, on behalf of ASTRO, and Ian M. Thompson, MD, director of the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio and the Glenda and Gary Woods Distinguished Chair in genitourinary oncology, on behalf of the AUA.
